Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

to discuss these results (see conference call details below).

"Our objective with R788 in RA is to position the product after methotrexate and before biological therapies are used. We have shown excellent results in that patient population in our earlier TASKi1 and TASKi2 studies, and we believe that patient population represents the large market opportunity for this product," said James M. Gower, chairman and chief executive officer of Rigel. "In this TASKi3 patient population, biologic failures, we have seen divergent results as sometimes happens in studies with subjective components. However, we are pleased to see excellent results in the objective measures and in the Synovitis and Osteitis MRI scores," he added.

*blood measurements of C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)

    Efficacy Results

    Treatment  N of Pts     ACR 20       ACR 50       ACR 70     DAS28<2.6
    ---------  --------     ------       ------       ------     ---------
    Placebo          73     27 (37%)      9 (12%)       4 (6%)      6 (10%)
    -------         ---     -------       ------        -----       ------
    100 mg bid      146     56 (38%)     32 (22%)      13 (9%)     15 (12%)
                             p=0.84       p=0.09       p=0.37       p=0.15
    ----------      --- ------------ ------------ ------------  -----------

    p=values compared to placebo
    Note: At 3 months. All patients were on stable doses of methotrexate
          throughout the clinical trial.



    MRI Results

    TASKi3 Mean Change from Baseline in RAMRIS* Scores at Month 3

                  Placebo      100 mg bid         p=values
                  -------      ----------         --------
    Synovitis**     +0.35            -0.52         p=0.038
    ----------      -----            -----         -------
    Osteitis**
     Score          +1.17            -0.19        
'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... -- A groundbreaking new, minimally invasive outpatient treatment option ... is now readily available to the estimated 1 million ... who suffer from this condition. ... leading practitioner of this safe, effective, Federal Drug Administration-approved ... new Los Angeles -area medical centers ...
(Date:4/21/2015)... 2015 Oxfordshire ... more than doubled its overseas sales in just 4 ... winning the Queen,s Award for Enterprise, for Outstanding Achievement ... first HealthScience Communications consultancy, helping its clients bring new ... Having more than doubled its exports in just 4 ...
(Date:4/21/2015)... Cardiologists at Henry Ford Hospital have implanted a ... an irregular heartbeat. With only handful of hospitals ... is able to add another option to its arsenal of ... heart,s ability to pump. "This is a ... Watchman implant at a non-clinical trial site," says cardiologist ...
Breaking Medicine Technology:New Minimally Invasive Treatment for Uterine Fibroids Offers Life-Changing Relief, Without a Hysterectomy, to 1 Million Southern California Women 2New Minimally Invasive Treatment for Uterine Fibroids Offers Life-Changing Relief, Without a Hysterectomy, to 1 Million Southern California Women 3New Minimally Invasive Treatment for Uterine Fibroids Offers Life-Changing Relief, Without a Hysterectomy, to 1 Million Southern California Women 4Queen's Award Crowns Achievements of Local Consultancy 2Queen's Award Crowns Achievements of Local Consultancy 3Queen's Award Crowns Achievements of Local Consultancy 4Queen's Award Crowns Achievements of Local Consultancy 5Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3
(Date:4/21/2015)... 2015 My Patriot Supply is proud ... latest innovation in home water filtration: Alexapure Pro™ ... that makes existing gravity-fed filters obsolete. An unprecedented advancement ... industry standards for water filtration. With an optimized flow ... typical household. , The Alexapure Pro™ takes a unique, ...
(Date:4/21/2015)... Sinking Spring, PA (PRWEB) April 21, 2015 ... neighboring Berks County commercial printer, Offset Impressions. ... with its full line of printing capabilities and knowledgeable ... Grafika. “This acquisition allows us to offer an ... addition to the labeling, packaging, and specialty services we ...
(Date:4/21/2015)... The California Healthcare Institute (CHI), ... sciences organizations, released the following statement by CHI ... Assembly Bill (AB) 463: , “As innovators in ... of treatments and cures for patients with serious ... AB 463, the so-called Pharmaceutical Cost Transparency Act ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Information is the ... Kevin Ryan, MD, FACP, empowers patients and their families with ... is the Rumor and Cancer is the Answer" and ... and informative language to guide patients from diagnosis through treatment ... patients active participants in their treatment, at home and in ...
(Date:4/21/2015)... 2015 The report “Dermatitis ... analysis on the therapeutic development for Dermatitis. ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
Breaking Medicine News(10 mins):Health News:Preparedness Leader My Patriot Supply Unveils the New Alexapure Pro™ Water Filter 2Health News:California Healthcare Institute Statement on AB 463 2Health News:California Healthcare Institute Statement on AB 463 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... Sept. 30 Heartland Information Services, a national provider ... Himes to President and Chief Executive Officer. Previously Chief ... the President and CEO position immediately. , Himes will ... who has accepted a new position with Reichert, Inc. ...
... NEW YORK (Sept. 30, 2009) -- New research by ... ways parents and peers influence teenagers to smoke, drink ... toward smoking influenced teenagers, use of multiple drugs (smoking, ... in boys and girls. For girls, friends were ...
... system made of billions of neurons and thousands of ... of the strongest emotions, fear. Most neurological fear studies ... Missouri researchers have started using computational models of the ... Guoshi Li, an electrical and computer engineering doctoral student, ...
... a third of U.S. victims were also infected with pneumococcus ... News) -- Bacterial co-infections are common among people who have ... probably contributed to their deaths, according to a new federal ... Control and Prevention analyzed lung tissue samples from 77 people ...
... U.S. Food and Drug Administration today announced the availability ... Evaluation and Mitigation Strategies or REMS, which are required ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , The Food and Drug ... the authority to require the submission and implementation of ...
... ARLINGTON, Va. and BOSTON, Sept. 30 On November 16, ... GO! and Boston creative group CloudKid, invite early elementary school ... and friends in FIZZY,S LUNCH LAB ( PBSKIDSGO.org/lunchlab ... good and bad food, and learn what happens once the ...
Cached Medicine News:Health News:Heartland Information Services Appoints New Chief Executive Officer 2Health News:Teen attitudes toward smoking linked to likelihood of drinking and using drugs 2Health News:Researchers use computational models to study fear 2Health News:CDC Links Infections With Swine Flu Deaths 2Health News:CDC Links Infections With Swine Flu Deaths 3Health News:FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies 2Health News:Video: Laughter is the Key Ingredient in 'FIZZY'S LUNCH LAB,' a New Health-Themed Web-Only Property Launching November 16 on PBSKIDSGO.org 2Health News:Video: Laughter is the Key Ingredient in 'FIZZY'S LUNCH LAB,' a New Health-Themed Web-Only Property Launching November 16 on PBSKIDSGO.org 3Health News:Video: Laughter is the Key Ingredient in 'FIZZY'S LUNCH LAB,' a New Health-Themed Web-Only Property Launching November 16 on PBSKIDSGO.org 4Health News:Video: Laughter is the Key Ingredient in 'FIZZY'S LUNCH LAB,' a New Health-Themed Web-Only Property Launching November 16 on PBSKIDSGO.org 5Health News:Video: Laughter is the Key Ingredient in 'FIZZY'S LUNCH LAB,' a New Health-Themed Web-Only Property Launching November 16 on PBSKIDSGO.org 6
... has been approved for use as an ... seizures in adults and adolescents over 12 ... that are refractory to antiepileptic medications. This ... controlled, clinical trials. Efficacy, measured as median ...
... Electrodes share similar characteristics with ... difference is that all of ... to assist you intraoperatively. In ... for use with either our ...
State-of-the-art sleep recording and analysis...
... workstation is a medical device designed to ... video capability, and archiving demands of the ... A framework that helps organize workflow and ... A centralized database and powerful search capability ...
Medicine Products: